Lv3
336 积分 2024-07-21 加入
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
12小时前
待确认
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
1个月前
已完结
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer
1个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
2个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
3个月前
已完结
[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)]
3个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
3个月前
已完结
皖公网安备34019202002308
